Premium
Antibody response to a non‐conserved C‐terminal part of human histone deacetylase 3 in colon cancer patients
Author(s) -
Shebzukhov Yuriy V.,
Koroleva Ekaterina P.,
Khlgatian Svetlana V.,
Belousov Pavel V.,
Kuz'mina Ksenia E.,
Radko Boris V.,
Longpre Fanny,
Lagarkova Maria A.,
Kadachigova Tatiana S.,
Gurova Olga V.,
Meshcheryakov Andrey A.,
Lichinitser Mikhail R.,
Knuth Alexander,
Jager Elke,
Kuprash Dmitry V.,
Nedospasov Sergei A.
Publication year - 2005
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.21240
Subject(s) - immunoscreening , antigen , histone deacetylase 2 , histone deacetylase , antibody , colorectal cancer , epitope , immune system , biology , immunology , cancer , cancer research , histone , medicine , complementary dna , cdna library , genetics , gene
Antibodies to cancer antigens can often be detected in the sera of patients, although the mechanism of the underlying humoral immune response is poorly understood. Using immunoscreening of tumor-derived cDNA expression libraries (SEREX), we identified human histone deacetylase 3 (HDAC3) as serologically defined antigen in colon cancer. Closely related HDAC1 and HDAC2 do not elicit humoral response in colon cancer patients. We show that the C-terminal region of HDAC3 protein lacking the homology to other Class I HDAC contains at least 3 distinct B-cell epitopes that are recognized by the serum antibodies. HDAC3 in combination with other SEREX antigens may become a useful molecular biomarker with diagnostic or prognostic value for a subset of colon cancer patients.